Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $33.65 According to Brokerages

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have been given an average recommendation of "Hold" by the twenty-two analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation, nine have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $33.65.

Several equities analysts have commented on RARE shares. Jefferies Financial Group cut their price objective on Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a "buy" rating on the stock in a research report on Thursday, September 3rd. UBS Group began coverage on Ultragenyx Pharmaceutical in a research note on Thursday, October 15th. They issued a "neutral" rating and a $16.00 target price on the stock. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Royal Bank Of Canada downgraded shares of Ultragenyx Pharmaceutical from a "moderate buy" rating to a "hold" rating in a research note on Thursday, September 3rd. Finally, Wells Fargo & Company downgraded shares of Ultragenyx Pharmaceutical from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $50.00 to $18.00 in a research note on Thursday, September 3rd.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE opened at $16.02 on Wednesday. Ultragenyx Pharmaceutical has a 1 year low of $12.73 and a 1 year high of $39.89. The firm has a 50-day simple moving average of $18.37 and a two-hundred day simple moving average of $23.51. The company has a market cap of $1.58 billion, a P/E ratio of -2.74 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating analysts' consensus estimates of ($1.22) by $0.32. The business had revenue of $214.00 million for the quarter, compared to the consensus estimate of $183.08 million. During the same period in the prior year, the company posted ($1.17) EPS. The company's quarterly revenue was up 28.5% compared to the same quarter last year. As a group, equities research analysts expect that Ultragenyx Pharmaceutical will post -3.97 EPS for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of the company's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $15.27, for a total value of $107,897.82. Following the transaction, the chief financial officer directly owned 89,229 shares in the company, valued at $1,362,526.83. This represents a 7.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 8,510 shares of company stock valued at $127,561. 5.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently modified their holdings of the stock. Versant Capital Management Inc raised its stake in shares of Ultragenyx Pharmaceutical by 662.9% during the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 1,001 shares in the last quarter. Quantbot Technologies LP bought a new position in Ultragenyx Pharmaceutical in the second quarter worth approximately $48,000. Harbor Investment Advisory LLC bought a new position in Ultragenyx Pharmaceutical in the second quarter worth approximately $52,000. Parallel Advisors LLC grew its stake in Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 1,440 shares in the last quarter. Finally, Leonteq Securities AG increased its holdings in Ultragenyx Pharmaceutical by 288.5% during the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 1,333 shares during the period. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. The company targets conditions with limited or no treatment options, including metabolic disorders, skeletal diseases and other inherited conditions. Its work includes the development of medicines, biologic therapies and gene therapy candidates intended to address the underlying causes or significant symptoms of these disorders.

Ultragenyx's commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Dojolvi (triheptanoin), a medical food used to manage long-chain fatty acid oxidation disorders; and Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.